NEUROONE MEDICAL TECHNOLOGIES Corp
About NEUROONE MEDICAL TECHNOLOGIES Corp
NeuroOne Medical Technologies Corp is focused on diagnostic, ablation, and deep brain stimulation technology for brain-related conditions such as epilepsy and Parkinson's disease; ablation and stimulation for pain management; and drug delivery with diagnostic and stimulation capabilities. It develops thin film electrode technology for various recording and therapeutic applications, crucial for diagnosing neurological disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors. The company operates in one segment, developing and commercializing products for neuromodulation, cEEG, and sEEG recording, monitoring, ablation, and brain stimulation, with revenue from Evo Cortical, Evo sEEG, and OneRF Ablation System.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $9.1M
- Net income
- -$3.6M
- Total assets
- $10.8M
- Market cap
- $29.7M
- Gross margin
- 56.5%
- Operating margin
- -46.5%
- Net margin
- -39.6%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $9.1M
- Cost of revenue
- $4.0M
- Gross profit
- $5.1M
- Operating expenses
- $12.4M
- Operating income
- -$4.2M
- Net income
- -$3.6M
- EPS (basic)
- $-0.09
- EPS (diluted)
- $-0.09
Balance sheet
- Total assets
- $10.8M
- Current assets
- $10.2M
- Total liabilities
- $3.7M
- Current liabilities
- $2.3M
- Shareholders’ equity
- $7.1M
Cash flow
- Operating cash flow
- -$2.8M
- Investing cash flow
- -$81.7K
- Financing cash flow
- $8.0M
- Net cash flow
- $5.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $29.7M
- EPS (diluted)
- $-0.09
- Shares outstanding
- 8.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 9, 2012
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $3.6M in FY2025.
- Revenue grew 5007% from FY2021 to FY2025.
- Gross margin of 56.5%, net margin -39.6%.
- Trading 46% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review NEUROONE MEDICAL TECHNOLOGIES Corp.
Write a review
News about NEUROONE MEDICAL TECHNOLOGIES Corp
News & sentiment via Polygon.io
